- Home
- QCRH vs MNKD Comparison
QCRH vs MNKD Comparison
Compare QCRH & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QCRH
- MNKD
- Stock Information
- Founded
- QCRH 1993
- MNKD 1991
- Country
- QCRH United States
- MNKD United States
- Employees
- QCRH N/A
- MNKD N/A
- Industry
- QCRH Major Banks
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- QCRH Finance
- MNKD Health Care
- Exchange
- QCRH Nasdaq
- MNKD Nasdaq
- Market Cap
- QCRH 1.2B
- MNKD 1.2B
- IPO Year
- QCRH 1993
- MNKD 2004
- Fundamental
- Price
- QCRH $78.96
- MNKD $4.11
- Analyst Decision
- QCRH Buy
- MNKD Buy
- Analyst Count
- QCRH 3
- MNKD 6
- Target Price
- QCRH $88.83
- MNKD $9.17
- AVG Volume (30 Days)
- QCRH 99.6K
- MNKD 3.0M
- Earning Date
- QCRH 07-23-2025
- MNKD 08-06-2025
- Dividend Yield
- QCRH 0.31%
- MNKD N/A
- EPS Growth
- QCRH N/A
- MNKD 149.32
- EPS
- QCRH 6.63
- MNKD 0.11
- Revenue
- QCRH $322,873,000.00
- MNKD $301,736,000.00
- Revenue This Year
- QCRH N/A
- MNKD $13.62
- Revenue Next Year
- QCRH $7.11
- MNKD $15.18
- P/E Ratio
- QCRH $11.85
- MNKD $37.98
- Revenue Growth
- QCRH N/A
- MNKD 21.48
- 52 Week Low
- QCRH $60.83
- MNKD $3.38
- 52 Week High
- QCRH $96.08
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- QCRH 70.85
- MNKD 60.67
- Support Level
- QCRH $74.50
- MNKD $3.60
- Resistance Level
- QCRH $76.17
- MNKD $3.99
- Average True Range (ATR)
- QCRH 1.52
- MNKD 0.15
- MACD
- QCRH 0.44
- MNKD 0.05
- Stochastic Oscillator
- QCRH 98.81
- MNKD 98.65
About QCRH QCR Holdings Inc.
QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely Quad City Bank & Trust (QCBT), Cedar Rapids Bank & Trust (CRBT), Community State Bank (CSB) and Guaranty Bank (GB). It generates revenue in the form of interest.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.